Check 35,000+ stocks against 26 valuation models and 37 quality factors

Repligen Corporation (RGEN) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Repligen Corporation $80.54, price $185, upside -56.4%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US7599161095

Some data Sep 23, 2026

Repligen Corporation

RGEN · US

Stretched ValuationQuality growthStrong overvaluation with only moderate quality.

!Fair value $80.54 · Strongly overvalued (−56%)

✓Quality 67/100

!Weak Growth (revenue 5y +15.0 %/yr)

!Thin margins · 6.7% net margin (TTM)

✓Low debt · generates free cash flow

!Trails peers (2/14)

!Narrow moat 39/100

!Evidence only medium, so the estimate is less certain

!Weak on past: 10 out of 100

26 models, one by oneBear $46.76 to bull $104.70 Growth analysisrevenue history, year by year Quality 67/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Repligen Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $102.87 – $324.21 · fair‑value band $46.76 – $104.70 · the $184.53 price screens above the $80.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Repligen in your weekly email

Every Wednesday you see whether Repligen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Stock analysis

Repligen Corporation (RGEN) currently trades at $184.53, while our model-based Fair Value estimate is $80.54, implying the stock looks roughly 129.1% overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $46.14 per share, and 0 of the 24 models we run sit above the $184.53 price.

Bear case: the Economic Profit group reads lowest at $9.02, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $46.76 (bear) to $104.70 (bull), the price of $184.53 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Repligen Corporation reported revenue of $738M in FY2025 versus $671M in FY2021, a compound +2.4%/yr. Reported net income was $48.9M in FY2025, compounding −21.4%/yr from FY2021.

Key figures

Market cap $10.4B · P/E ratio 202.8 · P/S ratio 13.4 · EPS (TTM) $0.9100 · Net margin 6.6% · Return on equity 2.5% · Return on assets (EBIT) 3.7% · Operating margin 8.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 1% below its 52-week high and 79% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −56%, RGEN screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($9.02 to $82.25). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.

Bear $46.76 Fair Value $80.54 Bull $104.70

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.6657 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

EPV $7.85 $9.02 $10.03 74

FCF DCF $31.95 $48.97 $102.02 73

Growth DCF $30.03 $56.78 $99.88 73

All 24 models by family

DCF Models

FCF DCF $31.95 $48.97 $102.02 73

Owner Earnings $37.34 $82.25 $173.05 68

5Y Revenue Exit $17.04 $26.41 $45.78 68

5Y EBITDA Exit $30.95 $54.53 $100.76 69

5Y P/E Exit $20.00 $39.86 $66.20 66

10Y Revenue Exit $21.37 $39.92 $49.71 65

10Y EBITDA Exit $31.71 $69.19 $134.25 62

10Y P/E Exit $23.90 $46.14 $81.00 59

Earnings-Based

Graham-Dodd $5.89 $41.11 $57.69 61

Lynch FV $21.24 $30.34 $39.44 59

PEG = 1.0 $21.24 $30.34 $39.44 55

EPV $7.85 $9.02 $10.03 74

Multiples

P/E Multiple $14.30 $19.07 $23.84 63

P/S Multiple $11.05 $14.74 $18.42 58

P/B Multiple $11.05 $14.74 $18.42 55

EV/EBIT $13.89 $18.38 $22.87 66

EV/EBITDA $29.56 $39.27 $48.99 67

EV/Revenue $10.03 $14.15 $18.27 54

Asset-Based

NCAV (Graham) $18.67 $25.02 $37.34 54

Growth DCF

Growth DCF $30.03 $56.78 $99.88 73

Rev-Margin DCF $18.60 $30.19 $54.65 68

Economic Profit

Residual Income $26.09 $24.77 $19.53 68

ROIC Compounder $7.85 $9.02 $10.03 70

Growth Earnings

Growth-Adj P/E $28.19 $40.27 $52.35 65

Open the full fair value analysis →

Notify me when RGEN reaches fair value

Put RGEN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 67/100

Of which business quality 66 · Market factors (momentum, volatility) 78

Profitability 23

Margins and returns on capital today

Quality Growth 80

Are margins and returns improving?

Cashflow 73

Earnings quality: real cash, not paper profit

Fin. Strength 73

Balance sheet, leverage, solvency risk

Investment 84

Disciplined investing over empire-building

Low Volatility 45

Calm price path (market factor)

Momentum 92

Price trend over the last 3–12 months (market factor)

52W Momentum 91

Distance to the 52-week high (market factor)

Net Issuance 79

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+16.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−2.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+15.0%

Start year 2020 (pandemic). Over 10 years: +24.3% a year

Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.2%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.

+0.3%

Earnings growth per share plus dividend.

Earnings per share, growth per year+0.3%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5% vs 12%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 8%

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+43.5%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+12.4%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +40.2% a year for the price and +9.8% for the forecasts.

Forecast 2026 (sales)+10.8%

Forecast 2027 (sales)+15.3%

Projected 2028 (sales)+13.6%

Projected 2029 (sales)+12.0%

Projected 2030 (sales)+10.3%

RGEN screens 129% overvalued. Compare with Intuitive Surgical, Inc →

Compare Repligen Corporation with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 2/14 measures

Overall it trails its industry peers.

Valuation

Quality Score 67 · Top 25%

Fair Value upside −56% · Bottom 25%

Profitability

Return on equity (TTM) 3% · Below median

Return on assets 1% · Below median

Net margin (TTM) 7% · Below median

Operating margin (TTM) 9% · Below median

Growth and dividend

Revenue growth 15% · Above median

Balance sheet

Debt / equity 0.26× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 202.8× · Priciest 25%

P/B 4.96× · Priciest 25%

P/S (TTM) 13.67× · Priciest 25%

P/FCF 111.2× · Priciest 25%

EV/EBITDA 77.6× · Priciest 25%

PEG 2.17× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 15

FUTURE (revenue growth)74 · sector 31

PAST (return on equity)10 · sector 25

HEALTH (low debt)87 · sector 96

DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$402.09	$353.38	−12%
EssilorLuxottica Société anonyme EL	€144.50	€158.95	+10%
Medline Inc MDLN	$34.43	$30.15	−12%
Becton, Dickinson and Company BDX	$183.00	$103.53	−43%
Alcon Inc ALC	$65.59	$39.78	−39%
ResMed Inc RMD	A$31.61	A$34.77	+10%
West Pharmaceutical Services, Inc WST	$371.09	$137.28	−63%
Sartorius Stedim Biotech S.A DIM	€206.40	€54.82	−73%
Straumann Holding STMN	CHF 97.86	CHF 45.50	−54%
Solventum Corporation SOLV	$88.75	$130.51	+47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Repligen Corporation · Fair Value
$80.54 −129%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/RGEN" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Repligen Corporation · Fair Value</span><br><b style="font-size:20px">$80.54</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−129%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Repligen Corporation Fair Value". https://www.fairvalue-calculator.com/stock/RGEN

Frequently asked questions

Is Repligen Corporation (RGEN) overvalued or undervalued?

As of Sep 23, 2026, our model estimates a fair value of $80.54 versus a price of $184.53, about −56% upside (overvalued).

What is the fair value of RGEN?

Our model-based fair value for Repligen Corporation is $80.54 (as of Sep 23, 2026), built from audited fundamentals. The current price: $184.53.

What is the quality score of RGEN?

Repligen Corporation has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Repligen Corporation (RGEN)?

Our model-based price target is the fair value of $80.54 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $46.76, optimistic scenario $104.70. It is a calculation from audited fundamentals, not an analyst target.

What is the Repligen Corporation stock forecast for 2026?

Our models put fair value at $80.54, about −56% upside versus a price of $184.53 (overvalued). Cautious scenario $46.76, optimistic scenario $104.70. The calculation is refreshed regularly with new filings.

What is the revenue of Repligen Corporation (RGEN)?

Repligen Corporation reported trailing-twelve-month revenue of about $763M (latest available figure, as of Sep 23, 2026).

What growth is priced into Repligen Corporation (RGEN)?

For today's price to be fair in a discounted-cash-flow model, Repligen Corporation would have to grow free cash flow by +43.5 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.1 % per year. As of Sep 23, 2026.

What discount rate (WACC) does the fair value of RGEN use?

Our models discount Repligen Corporation at 9.9 %: a base by market capitalisation (mid), damped by beta 1.06, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Repligen Corporation that is +43.5 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.

How much growth has Repligen Corporation (RGEN) delivered so far?

Over the past 5 years revenue at Repligen Corporation grew +15.1 % a year. The price currently implies +43.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Repligen Corporation (RGEN) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Repligen Corporation (+43.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Repligen Corporation (RGEN)?

The free-cash-flow yield on the price is 0.90 %: that much free cash flow Repligen Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Repligen Corporation (RGEN)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Repligen Corporation it is $80.54 per share (as of Sep 23, 2026), against a price of $184.53. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Repligen Corporation stock overvalued or undervalued in 2026?

As of Sep 23, 2026, RGEN trades above its calculated fair value: price $184.53, fair value $80.54, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of RGEN?

No. The price is what the market pays today ($184.53); the fair value is what the company's own numbers justify ($80.54). For Repligen Corporation the two are $103.99 per share apart. That gap is exactly why we show both numbers side by side.

How much is Repligen Corporation worth?

The market values Repligen Corporation at about $10.4B (market capitalisation, as of Sep 23, 2026). Per share that is $184.53; our models calculate a fair value of $80.54 per share.

What do the bullish and bearish scenarios say about RGEN?

Our models span a range for Repligen Corporation: cautious scenario $46.76, base $80.54, optimistic $104.70 per share (as of Sep 23, 2026, price $184.53). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of RGEN?

Repligen Corporation trades at a price-to-earnings ratio of 202.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $80.54 is built from several models across several years. Other multiples: PEG 2.2, P/B 5.0, P/S 13.7, EV/EBITDA 77.6.

What is the PEG ratio of RGEN?

The PEG ratio of Repligen Corporation is 2.17 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Repligen Corporation (RGEN)?

Balance-sheet figures for Repligen Corporation (as of Sep 23, 2026): return on equity 2.5%, debt of 0.26 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.

How far is RGEN from its 52-week high?

Repligen Corporation trades at $184.53, about 1% below its 52-week high of $186.75 and 79% above the low of $102.87 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $80.54 is for.

Which stocks are comparable to Repligen Corporation?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Repligen Corporation stock attractive at the current price?

The data as of Sep 23, 2026: price $184.53, calculated fair value $80.54 (−56%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of RGEN calculated?

We run Repligen Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $80.54, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Repligen Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Repligen Corporation (RGEN)?

The closing price on Sep 23, 2026 was $184.53. Our model-based fair value is $80.54, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Repligen Corporation right now?

The price sits above even our optimistic bull case ($104.70). The favourable scenario is already priced in. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($46.76 to $104.70) leaves room in how you read the outcome.

Where does the earnings growth of Repligen Corporation (RGEN) come from?

Earnings per share at Repligen Corporation grew +12.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +19.3 %, EBIT margin −7.1 %, tax rate −1.3 %, residual (interest, one-offs) +2.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Repligen Corporation

How large is the market capitalisation of Repligen Corporation (RGEN)?

The market capitalisation of Repligen Corporation is $10.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Repligen Corporation (RGEN)?

The price-to-sales ratio of Repligen Corporation is 13.4 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Repligen Corporation (RGEN)?

Earnings per share at Repligen Corporation are $0.9100 (price ÷ EPS = P/E 202.8). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Repligen Corporation (RGEN)?

The net margin of Repligen Corporation is 6.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Repligen Corporation (RGEN)?

The return on equity (ROE) of Repligen Corporation is 2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Repligen Corporation (RGEN)?

On an EBIT basis the return on assets of Repligen Corporation is 3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Repligen Corporation (RGEN)?

The operating margin of Repligen Corporation is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Repligen Corporation (RGEN)?

Revenue at Repligen Corporation is growing +14.8% versus a year earlier (3y avg −2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Repligen Corporation (RGEN)?

Earnings per share at Repligen Corporation are growing +47.9% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Repligen Corporation (RGEN) carry?

The net debt of Repligen Corporation is $124M (fiscal year 2025, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Repligen Corporation in the live analysis

One click puts Repligen Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.